Comparing the current results to its competitors, Bruker reported Revenue increase in the 2 quarter 2026 by 5.22 % year on year. The revenue growth was below Bruker's competitors' average revenue growth of 7.77 %, achieved in the same quarter.
Bruker Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 11.17 %
Bruker's Comment on Competition and Industry Peers
The company operates in multiple highly competitive markets experiencing industry consolidation. Some competitors have significantly greater financial, technical, and marketing resources, as well as more experience in the life sciences, chemical, and materials sectors. Competitors may develop products that render the company's products or those of its strategic partners obsolete or noncompetitive. Additionally, competitors may benefit from cost and price advantages due to currency fluctuations relative to the U.S. Dollar or Euro. The company's success depends on developing proprietary products that are timely, technologically advanced, and more cost-effective than competitors' offerings. Current competitors or other companies may possess or develop more effective technologies and products.
August 6, 2025
In a notable advancement for Bruker Corporation, the company has secured several multi-year contracts valued at over $27 million, specifically for its explosives and chemical trace detection solutions within the aviation and defense sectors. These agreements, finalized throughout 2025, represent a strategic initiative to bolster the capabilities of customers involved in aviation security and defense, aligning with heightened global demand for robust threat detection technologies. Key Developments: 1. Contract Achievements : The contracts encompass a wide array of Bruker’s offerings, including accessories, consumables, and service provisions. These contracts position Bruker as a key player in the crucial s...
April 17, 2025
Bruker Corporation Pushes Innovation Boundaries with nVista 2P, Faces Financial Challenges CSIMarket.com Bruker Corporation (Nasdaq: BRKR), a leader in scientific instrumentation, has unveiled its pioneering nVista 2P miniature two-photon microscope. Announced from San Jose, California, this state-of-the-art device represents a major advancement in the Inscopix product line, empowering researchers to capture high-resolution, three-dimensional images of neuronal activity in freely moving animals. This cutting-edge tool leverages two-photon fluorescence microscopy technology, allowing for imaging at greater depths and granting scientists the ability to gain unprecedented insights into the intricate workings...
April 16, 2025
In a strategic move to enhance its diagnostic capabilities, Bruker Corporation (NASDAQ: BRKR) has announced a majority investment in RECIPE Chemicals + Instruments GmbH. Based in Munich, Germany, RECIPE is a recognized leader in the production of mass spectrometry-based diagnostic assay kits, primarily geared towards therapeutic drug monitoring (TDM). A Strategic Fit By acquiring a controlling stake in RECIPE, Bruker aims to solidify its position in the diagnostics market, leveraging RECIPE s expertise in vendor-agnostic clinical in vitro diagnostic kits. These kits are essential for laboratories employing LCMSMS, HPLC, and ICPMS assays, offering them reliable tools for therapeutic drug monitoring. The acqui...
May 9, 2024
Bruker Corporation, a leading provider of scientific instruments and solutions, recently announced its plans to host an Investor Webinar on May 17, 2024. The webinar aims to shed light on the company s recent acquisitions, including Chemspeed, ELITech, and the NanoString business, while also addressing its medium-term financial outlook. The event will feature presentations by CEO Frank H. Laukien and CFO Gerald Herman. Additionally, Bruker s financial performance for the third quarter of 2023 reveals strong growth, surpassing its competitors in terms of revenue increase and profitability. This article analyzes Bruker s recent developments and provides insights into its overall market standing.Impressive Fina...
May 7, 2024
In a significant legal victory for NanoString Technologies Germany GmbH, the German Federal Patent Court has ruled in favor of the company by invalidating European Patent No. 2794928B1 (the 928 Patent) in Germany. This decision came in response to its assertion by 10x Genomics against NanoString in a patent infringement case. The court s ruling is a major win for NanoString and Bruker Corporation, which acquired NanoString Technologies, Inc on May 6th, 2024.Bruker Corporation, a leading provider of scientific instruments and solutions, reported a remarkable increase in revenue in the third quarter of 2023. The company s revenue rose by 16.26% year on year, surpassing the average revenue growth of its competi...
Agilent Technologies Inc. operates a business model centered on delivering innovative measurement solutions across industries like life sciences, diagnostics, and chemical analysis. Their revenue primarily comes from sales of instruments, software, and consumables, supplemented by support services. The company emphasizes strong partnerships and collaborations to enhance their market presence and influence.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Avantor Inc's business model revolves around providing a wide range of products, services, and solutions to customers in the life sciences, advanced technologies, and applied materials sectors. They focus on delivering a comprehensive offering, including chemicals, lab equipment, consumables, and customized solutions, to support research, development, and production processes.
10x Genomics Inc is a biotechnology company that specializes in providing tools and solutions for genomic research. Their business model revolves around developing innovative technologies and platforms to enable scientists and researchers to gain deeper insights into the structure and function of biological systems. They offer products such as single-cell sequencing and spatial transcriptomics to support various areas of genomics research and accelerate discoveries in fields like cancer research, immunology, and neuroscience.
Sources:
Bruker Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bruker Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
